Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BIOC / Biocept, Inc. ER

5h sec.gov
Mail Stop: 3561 November 28, 2017 Via E-mail Michael W. Nall Chief Executive Officer and President Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 Re: Biocept, Inc. Registration Statement on Form S-1 Filed November 17, 2017 File No. 333-221648 Dear Mr. Nall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. (17-0)

BIOC / Biocept, Inc. ESP

5h sec.gov
bioc-corresp.htm   Dawson James Securities, Inc. 1 North Federal Highway, 5th Floor Boca Raton, FL 33432   January 24, 2018   Via EDGAR   U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549   Re:Biocept, Inc. Registration Statement on Form S-1 File No. 333-221648   Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as placement agent for the proposed offeri (17-0)

BIOC / Biocept, Inc. ESP

5h sec.gov
bioc-corresp.htm   Biocept, Inc. 5810 Nancy Ridge Drive San Diego, CA 92121 (858) 320-8200   January 24, 2018   Via EDGAR   U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549   Re:Biocept, Inc. Registration Statement on Form S-1 File No. 333-221648   Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, Biocept, Inc. (17-0)

BIOC / Biocept, Inc. BIOC-8K-02122018 (Current Report)

2018-02-12 sec.gov
bioc-8k_20180206.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2018     BIOCEPT, INC. (Exact name of registrant as specified in its charter)                 Delaware   001-36284   80-0943522 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

BIOC / Biocept, Inc. / Sabby Management, LLC - SABBY 13G BIOC 02.01.18 (Passive Investment)

2018-02-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Biocept, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072V204 (CUSIP Number) January 26, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover p

BIOC / Biocept, Inc. / Sabby Management, LLC - SABBY 13G BIOC 02.01.18 (Passive Investment)

2018-02-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Biocept, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09072V204 (CUSIP Number) January 26, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover p

Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.

2018-01-31 accesswire
BOCA RATON, FL / ACCESSWIRE / January 31, 2018 / Dawson James Securities, Inc. in conjunction with Biocept, Inc. (NASDAQ: BIOC) announced today the closing of a "best efforts" public offering of 32,854,606 shares of common stock and warrants to purchase up to an aggregate of 32,854,606 shares of common stock at a combined offering price of $.045. The warrants have a per share exercise price of $.50, are exercisable immediately and will expire five years from the date of issuance. (17-1)

BIOC / Biocept, Inc. BIOC-8K-01302018 (Current Report)

2018-01-30 sec.gov
bioc-8k_20180130.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018     BIOCEPT, INC. (Exact name of registrant as specified in its charter)                 Delaware   001-36284   80-0943522 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

BIOC / Biocept, Inc. BIOC-424B4-012618 (Prospectus)

2018-01-26 sec.gov
bioc-424b4.htm    Filed Pursuant to Rule 424(b)(4) Registration No. 333-221648 PROSPECTUS 33,333,333 Shares of Common Stock Warrants to Purchase Up to 33,333,333 Shares of Common Stock   Biocept, Inc. is offering 33,333,333 shares of our common stock and warrants to purchase shares of our common stock, at a combined offering price of $0.45 per share of common stock and accompanying warrants. Each share of our common stock is being sold together with a warrant to purchase one share of our common

Biocept, Kimco Realty Tumble into Friday’s 52-Week Low Club

2018-01-26 247wallst
January 26, 2018: Here are four stocks trading with heavy volume among 44 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by around 8 to 7 and on the Nasdaq, advancers led decliners by almost 3 to 2. (31-2)

Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results

2018-01-26 seekingalpha
Today we will discuss Advaxis (ADXS), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The stock, though, had given up most of the gains in recent trading Friday. (348-5)

BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants

2018-01-26 reuters
* BIOCEPT ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OFFERING OF 33,333,333 SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 33,333,333 SHARES OF COMMON STOCK (17-2)

BIOC / Biocept, Inc. S-1MEF

2018-01-26 sec.gov
S-1MEF As filed with the Securities and Exchange Commission on January 26, 2018 Registration No. 333-                     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     Biocept, Inc. (Exact Name of Registrant as Specified in Its Charter)       Delaware   8071   80-0943522 (State or Other Jurisdiction of Incorporation or Organization)   (Primary Standard Industrial Classification Code Number)   (I.

Colony NorthStar, Kimco Realty Slide into Wednesday’s 52-Week Low Club

2018-01-24 247wallst
January 24, 2018: Here are four stocks trading with heavy volume among 29 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by around 8 to 7 and on the Nasdaq, decliners led advancers by more than 9 to 5. (40-0)

BIOC / Biocept, Inc. S-1/A #3

2018-01-24 sec.gov
S-1/A #3 Table of Contents As filed with the Securities and Exchange Commission on January 24, 2018 Registration No. 333-221648       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     Biocept, Inc. (Exact name of registrant as specified in its charter)       Delaware   8071   80-0943522 (State or other jurisdiction of incorporation or organization)   (Primary Standard Industrial Clas


BIOC : Biocept Stock Analysis and Research Report

Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” its current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic mutations that may qualify a subset of cancer patients for targeted therapy. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Biocept assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging.

Biocept current assays and planned future assays focus on key solid tumor indications utilizing its Target-Selectors liquid biopsy technology platform for the biomarker anal...

Click for full article
CUSIP: 09072V105